Geode Capital Management
SKYE icon

Geode Capital Management’s Skye Bioscience SKYE Stock Holding History

Geode Capital Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$151K Sell
27,257
-7,400
-21% -$46.5K ﹤0.01% 4002
2026
Q1 		$170K Buy
34,657
+8,388
+32% +$54.7K ﹤0.01% 3970
2025
Q4 		$158K Buy
26,269
+194
+0.7% +$2.27K ﹤0.01% 3987
2025
Q3 		$820K Buy
26,075
+835
+3% +$25.2K ﹤0.01% 3451
2025
Q2 		$844K Sell
25,240
-29,859
-54% -$494K ﹤0.01% 3382
2025
Q1 		$701K Buy
55,099
+4,387
+9% +$95.8K ﹤0.01% 3427
2024
Q4 		$1.15M Buy
50,712
+2,488
+5% +$83.2K ﹤0.01% 3324
2024
Q3 		$1.51M Buy
48,224
+1,952
+4% +$87.6K ﹤0.01% 3210
2024
Q2 		$2.97M Buy
+46,272
New +$4.39M ﹤0.01% 2987

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management's SKYE Position: Q2 2026 in Review

Geode Capital Management reduced its Skye Bioscience (SKYE) stake by 21% in Q2 2026, selling an estimated $46.5K and leaving 27,257 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #4002.

Geode Capital Management first reported a position in SKYE in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.97M in Q2 2024. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • Geode Capital Management held 27,257 shares of Skye Bioscience worth $151K as of Q2 2026.
  • Geode Capital Management sold 7,400 Skye Bioscience shares in Q2 2026, an estimated $46.5K.
  • Skye Bioscience made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4002 holding.
  • Geode Capital Management first reported a position in Skye Bioscience in Q2 2024 and has held it in 9 quarters since.
  • Geode Capital Management's Skye Bioscience position peaked at $2.97M in Q2 2024.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.